12-[[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]oxycarbonyl]heptadecanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 12-[[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]oxycarbonyl]heptadecanoic acid
• 化学式: C₃₇H₆₀O₅
• 分子量: 584.9
• InChiKey: DJUICMKCVLQWOS-ZGNMCRHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  42
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• FILM DELIVERY SYSTEM FOR ACTIVE INGREDIENTS
  申请人：MonoSol Rx LLC

  公开号：EP2968123A1

  公开（公告）日：2016-01-20
• US20140271867A1
  申请人：——

  公开号：US20140271867A1

  公开（公告）日：2014-09-18
• [EN] FILM DELIVERY SYSTEM FOR ACTIVE INGREDIENTS<br/>[FR] SYSTÈME D'APPORT DE PELLICULE POUR PRINCIPES ACTIFS
  申请人：MONOSOL RX LLC

  公开号：WO2014151975A1

  公开（公告）日：2014-09-25

  The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.